ArticleBMC microbiology2026
Changes in antimicrobial resistance of clinical isolates of Proteus, Morganella, and Providencia species from regional hospitals in Zhejiang Province, 2020 ~ 2024.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundProteus, Morganella, and Providencia species are important opportunistic pathogens associated with healthcare- and community-acquired infections, but their recent epidemiological and antimicrobial resistance trends in regional secondary hospitals remain insufficiently characterized. This study investigated the distribution and antimicrobial resistance patterns of these three genera collected from 34 regional medical institutions in Zhejiang Province, China, between 2020 and 2024.
methodsClinical isolates of these three genera were collected from 34 secondary-level hospitals across seven regions of Zhejiang. Bacterial identification and antimicrobial susceptibility testing were performed primarily using VITEK-2. Results were interpreted according to Clinical and Laboratory Standards Institute (CLSI) M100 breakpoints. Duplicate isolates from the same patient were excluded. Isolates resistant to meropenem or ertapenem were defined as carbapenem-resistant Enterobacterales (CRE).
resultsA total of 7,329 nonduplicate isolates were collected, including 6,181 Proteus (84.4%), 847 Morganella (11.6%), and 301 Providencia (4.1%). Annual isolate counts increased from 2020 to 2024. The leading specimen sources were urine (approximately 42%), respiratory tract specimens (approximately 28%), and wound and secretion specimens (approximately 12%); approximately 2% were from bloodstream infections. Across all years, carbapenem resistance was lowest in Proteus and Morganella but highest in Providencia. In 2020, resistance rates for multiple antibiotics were higher than in 2021, and they increased again by 2024. Phylogenetic analysis revealed that the human intestinal tract may serve as a reservoir for blaNDM-1-carrying Providencia spp. and carbapenemase genes are broadly disseminated across genetically diverse M. morganii strains.
conclusionsThe rising prevalence of these bacteria, particularly carbapenem-resistant Providencia, highlights an urgent need for enhanced antimicrobial stewardship and infection control in secondary hospitals. Ongoing resistance surveillance in community healthcare settings is essential to curb the spread of these resistant pathogens.
Indexed as
Identifiers
42919145What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.